CRP and metabolic syndrome: MAFLD subjects also showed significantly elevated cardiometabolic risk markers including dyslipidemia (triglycerides 0.98 ± 0.55 vs 0.73 ± 0.39 mmol/L, HDL-C 1.22 ± 0.26 vs 1.39 ± 0.29 mmol/L; both p < 0.001), and inflammation (CRP 3.11 ± 3.78 vs 1.55 ± 4.78 mg/L, p < 0.001), as detailed in Table 1.